UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008225
Receipt number R000009692
Scientific Title The effect of cilostazol on vasospasm after subarachnoid hemorrhage: a role for spreading depolarization
Date of disclosure of the study information 2012/08/01
Last modified on 2014/12/22 16:44:00

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of cilostazol on vasospasm after subarachnoid hemorrhage: a role for spreading depolarization

Acronym

The effect of cilostazol on vasospasm after subarachnoid hemorrhage

Scientific Title

The effect of cilostazol on vasospasm after subarachnoid hemorrhage: a role for spreading depolarization

Scientific Title:Acronym

The effect of cilostazol on vasospasm after subarachnoid hemorrhage

Region

Japan


Condition

Condition

subarachnoid hemorrhage

Classification by specialty

Neurosurgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study is conducted to examine cerebral vasospasm and cerebral microcirculation for patients treated with cilostazol.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Incidence of cerebral vasospasm in the cilostazol treated group.

Key secondary outcomes

Clinical outcome (The Modified Rankin Scale; mRS) 30 days and 90 days after the onset of the patients treated with cilostazol.
Incidence of cerebral vasospasm detected on angiography.
Cerebral microcirculation of patients treated with cilostazol.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The patients of subarachnoid hemorrhage are treated with cilostazol after clipping/coi embolization of ruptured cerebral aneurysm.

Interventions/Control_2

The patients of subarachnoid hemorrhage are not treated with cilostazol after clipping/coi embolization of ruptured cerebral aneurysm.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The patients after aneurysmal subarachnoid hemorrhage.
The patients treated with surgical clipping or coil embolizaion within 72 hours after the onset of subarachnoid henorrhage.

Key exclusion criteria

The patients treated with surgical clipping or coil embolizaion after 72 hours of the onset of subarachnoid henorrhage.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Michiyasu Suzuki

Organization

Yamaguchi University School of Medicine

Division name

Department of Neurosurgery and Clinical Neuroscience

Zip code


Address

1-1-1 Minami-Kogushi, Ube, Yamaguchi

TEL

0836-22-2295

Email

shirao@yamaguchi-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Sadahiro Nomura

Organization

Yamaguchi University School of Medicine

Division name

Department of Neurosurgery and Clinical Neuroscience

Zip code


Address

1-1-1 Minami-Kogushi, Ube, Yamaguchi

TEL

0836-22-2295

Homepage URL


Email

shirao@yamaguchi-u.ac.jp


Sponsor or person

Institute

Yamaguchi University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Yamaguchi University School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

山口大学医学部附属病院(山口県)


Other administrative information

Date of disclosure of the study information

2012 Year 08 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2012 Year 06 Month 21 Day

Date of IRB


Anticipated trial start date

2012 Year 10 Month 01 Day

Last follow-up date

2014 Year 11 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 06 Month 21 Day

Last modified on

2014 Year 12 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009692


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name